Boston Scientific Corporation vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Vanguard Total Stock Market Index Fund ETF trades at $371.87. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | VTI | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $374.36 |
52-Week Low | $42.63 | $305.74 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
VTI trades at $369.78, down 0.78% on the day, with a bullish technical signal supported by moving averages. The ETF provides comprehensive U.S. market exposure with over 3,400 stocks and an ultra-low 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and strong long-term performance history averaging nearly 10% annual returns over 25 years.
VTI offers diversified U.S. equity exposure with minimal costs, though its performance remains tied to broader market volatility. Key risks include economic downturns and interest rate sensitivity, while institutional adoption and positive media sentiment support its long-term appeal for core portfolio holdings.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →